基本信息
浏览量:65
职业迁徙
个人简介
Jean François Rossi
Jean-François Rossi is Professor of Hematology since 1993. He previously was medical oncologist in the Cancer Center of Montpellier from 1987 and became head of the Hematology Department from 1994 to 2012 at the University Hospital of Montpellier, France. He is now consultant at the University Hospital of Montpellier and at the University Hospital of Nîmes, and was associate professor at Suzhou University (China). Professor Rossi obtained his medical degree and his PhD from the University of Montpellier. He also untertook post-doctoral work at the Cancer Center in Tucson (BGM Durie), at the VUMC San Antonio (GR Mundy) and at the NCI (SA Rosenberg). Professor Rossi was certificated in Rhumatology, Immunology, Medical Oncology, and Hematology. He developed translational research (INSERM U1040, Instiitute of Biotherapy, professor Bernard Klein), particularly targeted therapy, immune therapy for B-cell malignancies, including anti-interleukin 6, anti-BAFF-APRIL anti-HB-EGF therapy, anti-CD20 modulation, cellular therapy, i.e., dendritic cells, T and activated/amplified NK cells from umbilical cord blood with new technology, and identifying active subpopulations (Martin Villalba, INSERM and EEC network CliNK). Professor Rossi is implicated in different scientific advisory boards from innovative start-up companies (BETAINNOV, ORIBASE PHARMA and URODELIA). With BETAINNOV, he participates to new immune functions through the MHC I complex in both dysimmune diseases and hematological malignancies. Professor Rossi is member of the American Society of Hematology, American Society of Clinical Oncology, European Bone Marrow Transplantation and was member of the American Society of Bone and Mineral Research. He is member of the Castleman Disease Collaborative Network (CDCN) scientific advisory board. Professor Rossi has published more than 189 peer-viewed articles in the field of immune therapy, identification of new biological targets in cancer, particularly in B-cell malignancies, in different hematology, immunology and cancer journals. He also serves as reviewer for different jounals in this field of research., France
Jean-François Rossi is Professor of Hematology since 1993. He previously was medical oncologist in the Cancer Center of Montpellier from 1987 and became head of the Hematology Department from 1994 to 2012 at the University Hospital of Montpellier, France. He is now consultant at the University Hospital of Montpellier and at the University Hospital of Nîmes, and was associate professor at Suzhou University (China). Professor Rossi obtained his medical degree and his PhD from the University of Montpellier. He also untertook post-doctoral work at the Cancer Center in Tucson (BGM Durie), at the VUMC San Antonio (GR Mundy) and at the NCI (SA Rosenberg). Professor Rossi was certificated in Rhumatology, Immunology, Medical Oncology, and Hematology. He developed translational research (INSERM U1040, Instiitute of Biotherapy, professor Bernard Klein), particularly targeted therapy, immune therapy for B-cell malignancies, including anti-interleukin 6, anti-BAFF-APRIL anti-HB-EGF therapy, anti-CD20 modulation, cellular therapy, i.e., dendritic cells, T and activated/amplified NK cells from umbilical cord blood with new technology, and identifying active subpopulations (Martin Villalba, INSERM and EEC network CliNK). Professor Rossi is implicated in different scientific advisory boards from innovative start-up companies (BETAINNOV, ORIBASE PHARMA and URODELIA). With BETAINNOV, he participates to new immune functions through the MHC I complex in both dysimmune diseases and hematological malignancies. Professor Rossi is member of the American Society of Hematology, American Society of Clinical Oncology, European Bone Marrow Transplantation and was member of the American Society of Bone and Mineral Research. He is member of the Castleman Disease Collaborative Network (CDCN) scientific advisory board. Professor Rossi has published more than 189 peer-viewed articles in the field of immune therapy, identification of new biological targets in cancer, particularly in B-cell malignancies, in different hematology, immunology and cancer journals. He also serves as reviewer for different jounals in this field of research., France
研究兴趣
论文共 110 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Vaccinesno. 3 (2023): 493-493
Hematology, Transfusion and Cell Therapy (2022): S8-S8
Hematology, Transfusion and Cell Therapy (2022): S19-S20
Sergey V Efimov,Natallia V Matsiyeuskaya,Olga V Boytsova,Luydmila Yu Akhieva, Elena V Kuntsevich, Anastasia A Troshina, Elena I Kvasova,Anton A Tikhonov,Nadezhda F Khomyakova, Francisco Harrison,Jean-François Rossi,Timothy C Hardman
Sergey V Efimov,Natallia V Matsiyeuskaya,Olga V Boytsova,Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova,Anton Tikhonov,Nadezhda F Khomyakova,Tim Hardman,Jean-François Rossi
Hematology, Transfusion and Cell Therapy (2021): S9
引用0浏览0引用
0
0
Hematology, Transfusion and Cell Therapy (2021): S9
JAMA Internal Medicine (2021)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn